• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Land & Buildings Nominates Donna Brandin and Jonathan Litt for Election to the Board of Lexington Realty Trust

    12/6/21 8:00:00 AM ET
    $CAH
    $CLI
    $EQR
    $LXP
    Other Pharmaceuticals
    Health Care
    Real Estate Investment Trusts
    Consumer Services
    Get the next $CAH alert in real time by email

    Believes Nominees Have the Independent Perspectives, Differentiated Real Estate Investment Experience and Shareholder-Focused Mindsets Needed to Help Reverse Lexington's Chronic Underperformance

    Objective and Independent New Voices are Needed in the Boardroom to Oversee Leadership Transition Process and Full Review to Determine the Right Path Forward for LXP

    LXP's Total Shareholder Returns Have Underperformed Proxy Peers and Industrial Peers by Nearly 500% During CEO's 18-year Tenure1

    Today Land & Buildings Investment Management, LLC (together with its affiliates, "Land & Buildings"), a significant shareholder of Lexington Realty Trust ("LXP," "Lexington" or the "Company") (NYSE:LXP), announced its nomination of two highly-qualified and experienced candidates, Donna Brandin and Jonathan Litt, for election to the LXP Board of Trustees (the "Board") at the upcoming 2022 Annual Meeting of Shareholders (the "Annual Meeting").

    Ms. Brandin is the former Chief Financial Officer of Equity Residential (NYSE:EQR), the largest public owner and operator of apartments in the United States. She also previously served as the Chief Financial Officer of The Lightstone Group, LLC, a privately held real estate investment company, and currently serves as a director and as the Chair of the Audit Committee at Nuveen Global Cities Real Estate Investment Trust, a public non-traded real estate investment company sponsored by Teachers Insurance and Annuity Association of America.

    Mr. Litt is the Founder and Chief Investment Officer of Land & Buildings Investment Management, and previously was Managing Director and Senior Global Real Estate Analyst at Citigroup. Mr. Litt also previously served as a director on the Boards of Taubman Centers, Inc. (NYSE:TCO) and Mack-Cali Realty Corporation (NYSE:CLI).

    In connection with its nominations, Land & Buildings stated:

    "Lexington's track record of underperformance speaks volumes. During the 18-year tenure of CEO T. Wilson Eglin, the management team and the Board have consistently failed to close the discount between the Company's net asset value and its share price, or deliver shareholder returns on par with peers. Further, LXP's earnings have declined by 60% during the same period and its dividend has been reduced by over 60%2. Inexplicably, Mr. Eglin has been paid more than $65 million in total compensation for overseeing this value destruction3.

    Instead of working constructively to address the concerns we raised as shareholders, Lexington's Board has demonstrated a preference for gamesmanship and for a public proxy contest aimed at preserving the status quo. Unfortunately, history has given shareholders no reason to believe that keeping the current Board in place will result in anything besides more of the same disappointing results.

    It is clear that there is urgent need for real, shareholder-driven board change at Lexington. That is why we have nominated these two individuals, both of whom would bring differentiated real estate investment experience and objective and independent perspectives to the Company. In addition, Jon's appointment would ensure a true shareholder representative would be present to help oversee critical decisions regarding the best path forward for LXP – including the CEO succession process and the formation of a committee focused on evaluating the best pathways to create and maximize value."

    Additional Biographical Information on Nominees

    Donna Brandin
    previously served as Chief Financial Officer of Equity Residential (NYSE:EQR), a residential property real estate investment trust, and Executive Vice President, Chief Financial Officer and Treasurer of The Lightstone Group, LLC, a privately held real estate investment company, from 2008 to June 2018. Ms. Brandin currently serves as a director and as the Chair of the Audit Committee at Nuveen Global Cities Real Estate Investment Trust, a public non-traded real estate investment company sponsored by Teachers Insurance and Annuity Association of America, since January 2018. Ms. Brandin has also served as Executive Vice President and Chief Financial Officer of Eastern Generation, LLC (f/k/a US Power Generating Company), a power generation company, Executive Vice President and Senior Vice President and Treasurer at Cardinal Health Inc. (NYSE:CAH), a distributor of pharmaceuticals and other medical supplies. Ms. Brandin served as an advisory board member of eRESI Mortgage, LLC , a residential mortgage company sponsored by a Prominent New York Family Office, from November 2019 to October 2021 and she served as a director and Chairman of the Audit Committee at Invesque Inc. (TSX:IVQ), a real estate investment company, from July 2019 to May 2021. Ms. Brandin holds a Bachelor of Science degree in Business Administration from Kutztown University and a Master of Science degree in Finance from St. Louis University. She is a certified public accountant and recently completed the Harvard Business School Executive Education Corporate Directors Certification Program.

    Jonathan Litt is the Founder and Chief Investment Officer of Land & Buildings Investment Management, LLC, a registered investment advisor specializing in publicly traded real estate and real estate related securities, which he founded in 2008. Prior to founding L&B Management, Mr. Litt was Managing Director and Senior Global Real Estate Analyst at Citigroup, where he was responsible for Global Property Investment Strategy, coordinating a 44-person team of research analysts located across 16 countries. Mr. Litt previously served on the Board of Directors of Taubman Centers, Inc. (NYSE:TCO), a former S&P MidCap 400 Real Estate Investment Trust engaged in the ownership, management and/or leasing of regional, super-regional and outlet shopping centers in the U.S. and Asia, from May 2018 to May 2019. He has served as a director of the Land & Buildings Offshore Fund, Ltd. since 2008. Mr. Litt previously served as a director of Mack-Cali Realty Corporation (NYSE:CLI), a leading owner, manager, and developer of office and class A residential real estate throughout the Northeast, from March 2014 to August 2016, and as a director of the Children with Dyslexia Scholarship Fund. Mr. Litt holds a Bachelor of Arts degree in Economics from Columbia University and a Master of Finance degree from New York University's Stern School of Business.

    CERTAIN INFORMATION CONCERNING THE PARTICIPANTS

    Land & Buildings Investment Management, LLC together with the other participants named herein (collectively, "Land & Buildings"), intends to file a preliminary proxy statement and accompanying WHITE proxy card with the Securities and Exchange Commission ("SEC") to be used to solicit votes for the election of its slate of highly-qualified director nominees at the 2022 annual meeting of shareholders of Lexington Realty Trust, a Maryland corporation (the "Company").

    LAND & BUILDINGS STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR.

    The participants in the proxy solicitation are anticipated to be Land & Buildings Capital Growth Fund, LP ("L&B Capital"), Land & Buildings GP LP ("L&B GP"), L&B Opportunity Fund, LLC ("L&B Opportunity"), Land & Buildings Investment Management, LLC ("L&B Management"), Jonathan Litt and Donna Brandin.

    As of the date hereof, L&B Capital directly owns 939,632 shares of common stock, par value $0.0001 per share, of the Company (the "Common Stock"). L&B GP, as the general partner of L&B Capital, may be deemed the beneficial owner of the 939,632 shares of Common Stock owned by L&B Capital. As of the date hereof, L&B Opportunity directly owns 147,736 shares of Common Stock. As of the date hereof, 3,475,399 shares of Common Stock were held in a certain account managed by L&B Management (the "Managed Account"). L&B Management, as the investment manager of each of L&B Capital and L&B Opportunity, and as the investment advisor of the Managed Account, may be deemed the beneficial owner of an aggregate of the 4,562,767 shares of Common Stock directly owned by L&B Capital, L&B Opportunity and held in the Managed Accounts. Mr. Litt, as the managing principal of L&B Management, may be deemed the beneficial owner of an aggregate of the 4,562,767 shares of Common Stock directly owned by L&B Capital, L&B Opportunity and held in the Managed Account. As of the date hereof, Ms. Brandin does not own any shares of Common Stock.

    _______________________________________________

    1
    Industrial Peers defined by Land & Buildings as STAG, MNR, PLD, DRE, FR, TRNO, REXR, EGP; Proxy Peers defined by the Company in its 2021 proxy statement (DEF 14A page 28) as competitor peer group EGP, EPRT, FR, GTY, NNN, OLP, PSB, REXR, STAG, STOR, TRNO, VER, WPC. Total shareholder returns through August 16, 2021, the day Land & Buildings' investment in LXP was disclosed in Form 13F.

    2 FFO growth based on 2021 consensus estimates from Bloomberg for current year and reported FFO as sourced by SEC filings and Bloomberg for prior years. Dividends based on expected full year 2021 regular cash dividends based on dividend run rates and prior year disclosed regular cash dividends.

    3 Based on Company Annual Proxy statements.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20211206005189/en/

    Get the next $CAH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAH
    $CLI
    $EQR
    $LXP

    CompanyDatePrice TargetRatingAnalyst
    Equity Residential
    $EQR
    7/7/2025$75.00In-line → Outperform
    Evercore ISI
    Cardinal Health Inc.
    $CAH
    6/3/2025$179.00Equal Weight → Overweight
    Wells Fargo
    Cardinal Health Inc.
    $CAH
    2/5/2025$140.00 → $150.00Hold → Buy
    Jefferies
    Cardinal Health Inc.
    $CAH
    1/8/2025$130.00 → $144.00Hold → Buy
    TD Cowen
    Cardinal Health Inc.
    $CAH
    1/7/2025$140.00In-line → Outperform
    Evercore ISI
    Cardinal Health Inc.
    $CAH
    1/6/2025$132.00 → $145.00Neutral → Buy
    BofA Securities
    Equity Residential
    $EQR
    12/17/2024$83.00Overweight
    Barclays
    Cardinal Health Inc.
    $CAH
    12/13/2024$101.00 → $127.00Underweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $CAH
    $CLI
    $EQR
    $LXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Equity Residential upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Equity Residential from In-line to Outperform and set a new price target of $75.00

    7/7/25 8:10:48 AM ET
    $EQR
    Real Estate Investment Trusts
    Real Estate

    Cardinal Health upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Cardinal Health from Equal Weight to Overweight and set a new price target of $179.00

    6/3/25 7:24:57 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health upgraded by Jefferies with a new price target

    Jefferies upgraded Cardinal Health from Hold to Buy and set a new price target of $150.00 from $140.00 previously

    2/5/25 7:09:45 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    $CLI
    $EQR
    $LXP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Financial Officer Garechana Robert bought $279 worth of Common Shares Of Beneficial Interest (4 units at $69.81), increasing direct ownership by 0.03% to 14,112 units (SEC Form 4)

    4 - EQUITY RESIDENTIAL (0000906107) (Issuer)

    3/26/25 4:10:10 PM ET
    $EQR
    Real Estate Investment Trusts
    Real Estate

    Director Gupta Arun bought $134,250 worth of shares (15,000 units at $8.95), increasing direct ownership by 30% to 65,474 units (SEC Form 4)

    4 - LXP Industrial Trust (0000910108) (Issuer)

    6/14/24 4:03:37 PM ET
    $LXP
    Real Estate Investment Trusts
    Real Estate

    $CAH
    $CLI
    $EQR
    $LXP
    SEC Filings

    View All

    SEC Form 8-K filed by Cardinal Health Inc.

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    8/14/25 5:06:21 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form FWP filed by Cardinal Health Inc.

    FWP - CARDINAL HEALTH INC (0000721371) (Subject)

    8/13/25 4:44:29 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form 424B3 filed by Cardinal Health Inc.

    424B3 - CARDINAL HEALTH INC (0000721371) (Filer)

    8/13/25 8:51:32 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    $CLI
    $EQR
    $LXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sterrett Stephen E was granted 1,852 units of Common Shares Of Beneficial Interest, increasing direct ownership by 10% to 21,275 units (SEC Form 4)

    4 - EQUITY RESIDENTIAL (0000906107) (Issuer)

    8/18/25 4:16:21 PM ET
    $EQR
    Real Estate Investment Trusts
    Real Estate

    Chief Accounting Officer Kaufman Ian was granted 37 units of Common Shares Of Beneficial Interest, increasing direct ownership by 0.14% to 25,720 units (SEC Form 4)

    4 - EQUITY RESIDENTIAL (0000906107) (Issuer)

    8/18/25 4:11:40 PM ET
    $EQR
    Real Estate Investment Trusts
    Real Estate

    EVP & Chief Financial Officer Mcleod Bret was granted 19,564 units of Common Shares Of Beneficial Interest (SEC Form 4)

    4 - EQUITY RESIDENTIAL (0000906107) (Issuer)

    8/12/25 4:54:02 PM ET
    $EQR
    Real Estate Investment Trusts
    Real Estate

    $CAH
    $CLI
    $EQR
    $LXP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Aug. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2025 to shareholders of record at the close of business on October 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator o

    8/15/25 4:40:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance

    Fourth quarter revenue was relatively flat at $60.2 billion; revenue increased 21% excluding the impact of a previously communicated contract expirationFourth quarter GAAP1 operating earnings were $428 million and GAAP diluted EPS was $1.00Fourth quarter non-GAAP operating earnings increased 19% to $719 million and non-GAAP diluted EPS increased 13% to $2.08Fiscal Year 2025 adjusted free cash flow was $2.5 billionFiscal year 2026 non-GAAP EPS guidance2 raised to $9.30 to $9.50, from $9.10 to $9.30Company announces the acquisition of Solaris Health, the country's leading urology MSODUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported fourth quarter fiscal year

    8/12/25 6:55:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health announces the addition of Solaris Health, the country's leading urology MSO, to The Specialty Alliance

    Adds over 750 providers to Cardinal Health's multi-specialty MSO platform, The Specialty AllianceJoins with recent urology acquisitions to bolster The Specialty Alliance's leadership in the urology therapeutic areaCardinal Health MSO platforms reach ~3,000 providers in 32 states upon transaction close DUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced that The Specialty Alliance, its multi-specialty management services organization (MSO) platform, has entered into a definitive agreement to acquire Solaris Health, the country's leading urology MSO, from Lee Equity Partners and Solaris Health physician owners.

    8/12/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    $CLI
    $EQR
    $LXP
    Leadership Updates

    Live Leadership Updates

    View All

    Equity Residential Appoints Chris Carr to Board of Trustees

    Equity Residential (NYSE:EQR) today announced the appointment of Chris Carr to the Company's Board of Trustees to serve until the next annual meeting of shareholders. Mr. Carr qualifies as an independent trustee under the New York Stock Exchange's listing standards. He will serve on the Company's Audit and Corporate Governance Committees. With this appointment, the Company's Board will increase to 11 members, nine of whom are independent. Mr. Carr, 61, is the former Chief Operating Officer of Sweetgreen, Inc. (NYSE:SG), a restaurant and lifestyle brand. Prior to Sweetgreen, he held a variety of retail and supply chain senior executive roles at Starbucks (NASDAQ:SBUX), most recently as the

    7/24/25 4:15:00 PM ET
    $EQR
    $HLT
    $SBUX
    Real Estate Investment Trusts
    Real Estate
    Hotels/Resorts
    Consumer Discretionary

    Equity Residential Announces Executive Management Team Leadership Transition Plans

    Bob Garechana to become Chief Investment Officer; Bret McLeod joins as Chief Financial Officer; Alec Brackenridge to Retire as Chief Investment Officer Equity Residential (NYSE:EQR) today announced changes to its executive management team. Chief Investment Officer Robert A. ("Bob") Garechana, 46, currently the Company's Executive Vice President and Chief Financial Officer ("CFO"), will assume the role of Executive Vice President and Chief Investment Officer ("CIO"). Alexander ("Alec") Brackenridge, 61, currently Executive Vice President and CIO, will transition to Executive Vice President – Investments and retire at the end of 2025. Mr. Garechana joined Equity Residential in 2004 and

    6/30/25 8:30:00 AM ET
    $EQR
    $HST
    Real Estate Investment Trusts
    Real Estate

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CAH
    $CLI
    $EQR
    $LXP
    Financials

    Live finance-specific insights

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Aug. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2025 to shareholders of record at the close of business on October 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator o

    8/15/25 4:40:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance

    Fourth quarter revenue was relatively flat at $60.2 billion; revenue increased 21% excluding the impact of a previously communicated contract expirationFourth quarter GAAP1 operating earnings were $428 million and GAAP diluted EPS was $1.00Fourth quarter non-GAAP operating earnings increased 19% to $719 million and non-GAAP diluted EPS increased 13% to $2.08Fiscal Year 2025 adjusted free cash flow was $2.5 billionFiscal year 2026 non-GAAP EPS guidance2 raised to $9.30 to $9.50, from $9.10 to $9.30Company announces the acquisition of Solaris Health, the country's leading urology MSODUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported fourth quarter fiscal year

    8/12/25 6:55:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Equity Residential Reports Second Quarter 2025 Results

    Guidance Updated to Reflect Solid Operating Fundamentals Equity Residential (NYSE:EQR) today reported results for the quarter and six months ended June 30, 2025. Second Quarter 2025 Results All per share results are reported as available to common shares/units on a diluted basis.                                     Quarter Ended June 30,           2025     2024     $ Change     % Change       Earnings Per Share (EPS)   $ 0.50  

    8/4/25 4:15:00 PM ET
    $EQR
    Real Estate Investment Trusts
    Real Estate

    $CAH
    $CLI
    $EQR
    $LXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Equity Residential

    SC 13G/A - EQUITY RESIDENTIAL (0000906107) (Subject)

    11/14/24 1:22:34 PM ET
    $EQR
    Real Estate Investment Trusts
    Real Estate

    Amendment: SEC Form SC 13G/A filed by LXP Industrial Trust

    SC 13G/A - LXP Industrial Trust (0000910108) (Subject)

    11/12/24 10:32:13 AM ET
    $LXP
    Real Estate Investment Trusts
    Real Estate

    SEC Form SC 13G filed by LXP Industrial Trust

    SC 13G - LXP Industrial Trust (0000910108) (Subject)

    11/1/24 3:48:58 PM ET
    $LXP
    Real Estate Investment Trusts
    Real Estate